Cerus (CERS) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Cerus Corporation Announces Record Fourth Quarter and Full Year 2018 Results
February 26, 2019 4:02 PM ESTCONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2018.
Recent developments and highlights include:
Record fourth quarter product revenue of $16.5 million. Provided 2019 annual product revenue guidance of $70 million to $73 million, representing a 15% to 20% increase over 2018 reported product revenue. Filed CE Mark registration for the Companys INTERCEPT Blood System for red blood cells (RBCs). Initiated enrollment in ReCePI, Cerus U.S.... More